Literature DB >> 20857493

Characterization of metastatic breast cancer patients with nondetectable circulating tumor cells.

Michal Mego1, Ugo De Giorgi, Shahenaah Dawood, Xuemei Wang, Vicente Valero, Eleni Andreopoulou, Beverly Handy, Naoto T Ueno, James M Reuben, Massimo Cristofanilli.   

Abstract

Circulating tumor cells (CTC) are an independent prognostic factor in metastatic breast cancer patients (MBC). However, CTC are undetectable in one third of patients. The aim of this study was to assess the prognostic factors in MBC patients without detectable CTC. This retrospective study included 292 MBC patients evaluated between January 2004 and December 2007. CTC were enumerated before patients started a new line of treatment using the CellSearch™. Overall survival (OS) was calculated from the date of CTC measurement and estimated by the Kaplan-Meier product limit method. CTC were not detected in 35.96% patients, whereas 40.75% patients had CTC ≥ 5. Undetectable CTC status was positively correlated with presence of brain metastasis (OR: 6.17, 95%CI = 2.14-17.79; p = 0.001), and inversely correlated with bone metastasis (OR: 0.47; 95%CI = 0.27-0.80; p = 0.01). In multivariate analysis, hormone receptors, number of metastatic sites and lines of therapy were independent prognostic factors for OS in patients without detectable CTC. Patients without detectable CTC before starting of a new line of therapy comprise a heterogeneous group with substantially different prognosis. We showed that some important metastatic disease characteristics are predictive of undetectable CTC status in MBC.
Copyright © 2010 UICC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20857493     DOI: 10.1002/ijc.25690

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  56 in total

1.  Circulating tumor cells: highlight on practical implications.

Authors:  Paola Gazzaniga; Cristina Raimondi; Angela Gradilone; Giuseppe Naso; Enrico Cortesi; Luigi Frati
Journal:  Mol Diagn Ther       Date:  2012-02-01       Impact factor: 4.074

2.  Circulating tumor cells: finding the needle in the haystack.

Authors:  Xiaoning Zhe; Michael L Cher; R Daniel Bonfil
Journal:  Am J Cancer Res       Date:  2011-06-01       Impact factor: 6.166

Review 3.  Brain metastasis: new opportunities to tackle therapeutic resistance.

Authors:  Joan Seoane; Leticia De Mattos-Arruda
Journal:  Mol Oncol       Date:  2014-06-02       Impact factor: 6.603

4.  Heterogeneity of ERα and ErbB2 Status in Cell Lines and Circulating Tumor Cells of Metastatic Breast Cancer Patients.

Authors:  Carolin Bock; Brigitte Rack; Christina Kuhn; Simone Hofmann; Charlotte Finkenzeller; Bernadette Jäger; Udo Jeschke; Sophie F Doisneau-Sixou
Journal:  Transl Oncol       Date:  2012-12-01       Impact factor: 4.243

5.  Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer.

Authors:  Cristina Raimondi; Chiara Nicolazzo; Angela Gradilone; Giuseppe Giannini; Elena De Falco; Isotta Chimenti; Elisa Varriale; Siegfried Hauch; Linda Plappert; Enrico Cortesi; Paola Gazzaniga
Journal:  Cancer Biol Ther       Date:  2014-02-12       Impact factor: 4.742

6.  Prognostic significance of circulating tumor cells in advanced non-small cell lung cancer patients treated with docetaxel and gemcitabine.

Authors:  O Juan; J Vidal; R Gisbert; J Muñoz; S Maciá; J Gómez-Codina
Journal:  Clin Transl Oncol       Date:  2013-11-12       Impact factor: 3.405

Review 7.  CD133: to be or not to be, is this the real question?

Authors:  Elena Irollo; Giuseppe Pirozzi
Journal:  Am J Transl Res       Date:  2013-09-25       Impact factor: 4.060

8.  Factors related to biopsy willingness in patients with advanced cancer in a phase 1 clinic for molecularly targeted therapy.

Authors:  David S Hong; Goldy C George; Eucharia C Iwuanyanwu; Bahareh Tavana; Gerald S Falchook; Sarina A Piha-Paul; Jennifer J Wheler; Reena H Mistry; Xiudong Lei; Razelle Kurzrock
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-02       Impact factor: 4.553

Review 9.  Biophysical technologies for understanding circulating tumor cell biology and metastasis.

Authors:  Derrick W Su; Jorge Nieva
Journal:  Transl Lung Cancer Res       Date:  2017-08

Review 10.  The biological and clinical importance of epithelial-mesenchymal transition in circulating tumor cells.

Authors:  Huiying Liu; Xiaofeng Zhang; Jun Li; Bin Sun; Haihua Qian; Zhengfeng Yin
Journal:  J Cancer Res Clin Oncol       Date:  2014-06-26       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.